Basel, October 27, 2024 – Novartis today presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology (ASN) Kidney Week 2024 showing that patients with C3 ...

Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its ...

Not long after Basel, Switzerland, was selected as the next host of the annual Eurovision Song Contest, hometown pharma ...

(Reuters) - Swiss pharmaceutical giant Novartis will pay Monte Rosa Therapeutics $150 million upfront payment for a global license to develop, manufacture and sell some drug candidates, the U.S ...

ZURICH (Reuters) - Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday, with the pharmaceuticals giant ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.